Pre-clinical knowledge have proven that Molnupiravir has broad anti-influenza exercise, together with extremely potent inhibition of SARS-CoV-2 replication Natco Pharma share value hits 20 per cent higher circuit at Rs 1,188.95 apiece, additionally its all-time excessive, in intraday on BSE, after the corporate initiated part III medical trial to judge the efficacy and security of